DOCSLIB.ORG

Retzlaff Steps Down in Stada Shake-Up

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Retzlaff Steps Down in Stada Shake-Up Q&A session Spotlight on Leading with Tim Lahurque Pfizer to a Templeman International newfuture page 21 page 7 page 24 Contents Retzlaff steps down 9September 2016 Issue Number 468 in Stada shake-up COMPANY NEWS tada’sHartmut Retzlaff has resigned J&J researching skin treatments 3 Sfrom his position as chairman of the man- George to lead Stada Brands 4 agement board at the German company “due Perrigo reviews options 5 to personal circumstances”. Sanofi prepares for6The move came shortly before Stada an- growth in Australia nounced the make-up of its newsupervisory Latin America lifts 8 board following aperiod of instability after minor- turnoveratMerck ity shareholder Active Ownership’sattempts to gain control of the committee (OTC bulletin, Boehringer reports OTCrise 9 27 May 2016, page 6). Amazon Dash enters EU 12 In June, Stada announced that Retzlaffhad taken leave from his role as chief executive officer GENERAL NEWS at the firm “due to aserious, long-term illness” (OTC bulletin,17June 2016, page 27). Hartmut Retzlaff Homoeopathygets 13 Executive board member Matthias Wieden- Following the vote, fivenew members joined trade body support fels has taken overthe chief executive officer the supervisory board, four of which had been FDAissues revised 16 role “until further notice”, along with responsi- nominated by Stada. Only Eric Cornut, Nov- supplement rules bility for corporate strategy and production. artis’ former chief ethics, compliance and poli- ASMI welcomes 17 Joining Stada in 1986 as sales and market- cy officer,was elected from the list of candi- labelling changes ing director for its Stadapharm division, Retz- dates drawn up by Active Ownership. laffbecame head of Stadapharm in 1991. He Joining Cornut on the board are Stada can- MARKETING NEWS stepped up to lead the German group two didates: Rolf Hoffmann, former senior vice- years later,and in September last year,Stada president of US commercial operations at Am- Lanes strengthens Earex in UK 19 extended Retzlaff’semployment contract by gen; Dr Birgit Kudlek, previously chief operat- Regaine adds foam 19 fiveyears until August 2021 (OTC bulletin, ing officer at Aenova;Tina Müller,chief mar- in Germany 25 September 2015, page 23). keting officer at car manufacturer Opel; and Awards reflect digital growth 22 Shortly after Retzlaffstepped down, Stada Dr Gunnar Riemann, previously head of En- thwarted attempts by Active Ownership to re- vironmental Science at Bayer Crop Science. REGULARS place the majority of the company’ssupervisory Stada’sCarl Oetker has been elected chair- board with its owncandidates. manofthe supervisory board, replacing Martin Spotlight on –Lahurque 7 Prior to avote at the company’sannual Abend, who wasremovedatthe meeting. Q&A –with Boehringer 21 general meeting, Stada had warned that Active Meanwhile, Stada announced that Dieno Ingelheim’sTim Templeman Ownership’sdesire to replace six supervisory George had been promoted to takecharge of Events –Our regular listing 23 board directors would be a“disruptive action”, the firm’sBranded Products unit as part of a People –Recordati changes 27 as well as “ill-considered and irresponsible” “fundamental change to the firm’sreporting management team (OTC bulletin,12August 2016, page 23). structure” (see page 4). OTC Connect with us on: Twitter LinkedIn OTC-bulletin.com Areyour challenges giving you sleepless nights? Data ignites action. Action powers growth. Growth Delivered starts here. Get beyond information and insight to reveal whatitmeans for your business future. To hear about how we can help you deliver growth, visit www.IRIworldwide.com COMPANY NEWS OTC Licensing Agreements Business Strategy Mundipharma J&J is researching grows in MEA treatments for skin undipharma has broadened its OTC prod- Muct portfolio in the Middle East and Africa ohnson & Johnson (J&J) Consumer has by striking a licensing deal with Jordan-based Jpartnered with development company Xy- Munir Sukhtian group. crobe Therapeutics to research new treatments Under the terms of the agreement, UK-based for skin conditions. Mundipharma has gained the commercial rights Thepartnership, the US-based firm said, would for 10 years to market Munir Sukhtian’s HiGeen focus on “further understanding applications of consumer healthcare brand in more than 50 coun- Xycrobe’s platform technology developed for J&J will work with Xycrobe Therapeutics tries across the Middle East and Africa. the treatment of inflammatory skin diseases”. better solutions,” Hitchcock added. The HiGeen line includes foot creams and “The planned collaboration is intended to “The current paradigm for treating skin con- powders, as well as hand sanitisers and creams. provide both companies with information on how ditions, such as acne, completely disregards “The HiGeen range complements very well Xycrobe’s technology may be best applied to the importance of the commensal skin flora,” our consumer health portfolio, which includes future therapeutic and commercial applications,” Hitchcock argued. our Betadine range,” commented Raman Singh, J&J explained. “Overuse of antibiotics has led to a higher president of Mundipharma in Asia-Pacific, According to California-based Xycrobe, its prevalence of resistant strains of bacteria,” he Latin America, Middle East and Africa. “The platform technology “consists of a library of insisted, “and along with that comes less effi- partnership will also help Mundipharma build commensal [bacterial] strains from the skin cacy of conventional treatments.” on our strong leadership in the sector and help microbiome engineered to grow and secrete bio- “Wefeelthatthekeytobettertreatmentsolu- expand our presence.” therapeutics as needed to help treat an array of tions for skin disease lies in understanding our “Mundipharma’s expertise in emerging mar- skin issues”. body’s interaction with the skin microbiome,” kets,” continued Singh, “will increase access The company says it has developed “several Hitchcock explained, “and how we can leverage to these treatments for millions of people.” strains of commensal skin bacteria that show this information.” Deemah Sukhtian, Munir Sukhtian’s man- potential for the significant reduction of inflam- The partnership was facilitated by J&J In- ging director, claimed the “complementary na- mation, promising potential relief from a num- novation, the firm’s venture capital arm which ture” of HiGeen with Mundipharma’s products ber of ailments including acne, dermatitis, ec- aspires to find “the best science and technology, would “provide a stronger proposition to con- zema and psoriasis”. no matter where it is, to solve the greatest unmet sumers in the area of wound care and prevention Commenting on the partnership, Thomas needs of our time”. of infectious diseases”. Hitchcock, Xycrobe’s chief executive officer, Most recently, the Innovation unit partici- “We are confident that our alliance, leveraging said the company was “thrilled” to collabo- pated in a round of funding for the US-based Mundipharma’s expertise and global network,” rate with J&J Consumer. firm First Aid Shot Therapy (FAST) to help the Sukhtian added, “will enhance access to our inno- “It is our hope that this collaboration can fledgling company expand its portfolio of single- vative products and further improve the quality help expedite getting our therapies into the hands dose liquid OTC medicines (OTC bulletin, 27 of life of consumers.” OTC of physicians and their patients who truly need November 2015, page 4). OTC Editor: Matt Stewart Production Editor: Jenna Meredith Advertising Controller: Debi Minal Contributing Editor: David Wallace Director of Subscriptions: Val Davis Assistant Editor: Tom Gallen Editor-in-Chief: Aidan Fry Group Sales Manager: Rob Coulson Assistant Editor: Marie McEvoy Managing Director: Mike Rice Awards Manager: Natalie Cornwell 9 September 2016 | Number 468 Editorial enquiries: OTC bulletin, Te rms & Conditions: While due care has been taken to ensure the accuracy of 4 Poplar Road, Dorridge, Solihull, These can be viewed in full at www.OTC-bulletin.com. information contained in this publication, the publisher West Midlands B93 8DB, UK. No part of this publication may be copied, reproduced, makes no claim that it is free of error and disclaims any Website: www.OTC-bulletin.com stored in a retrieval system, distributed or transmitted by liability whatsoever for any decisions or actions taken as a result of its contents. Te l: +44 (0)1564 777550 any means, including electronic, mechanical, photocopying Fax: +44 (0)1564 777524 or recording, without the prior written permission of © OTC Publications Ltd. All rights reserved. the publisher, or under the terms and conditions of Email: [email protected] ® a Global Site Licence or of a licence issued by the OTC bulletin is registered as a trademark in the European Community. Advertising enquiries: Copyright Licensing Agency (CLA) in London, UK, or Contact: [email protected] rights bodies in other countries that have reciprocal ISSN 1350-1097. Subscription enquiries: agreements with the CLA. Company registered in England No 2765878. Subscription rates are published at Neither may this publication be exported, distributed www.OTC-bulletin.com/subscribe. or circulated by any means without the prior written Printed by Warwick Printing Company Limited, Contact: [email protected] permission of the publisher. Leamington Spa CV31 1QD, UK. 9 September 2016 OTC bulletin 3 OTC COMPANY NEWS Business Strategy/First-Half Results George to lead Stada Brands ieno George has
Load more

Recommended publications
  • Betterbusiness Betterfinancials How We Drive Growth and Outperformance
    Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.
    [Show full text]
  • Rejuvenating RB Plc Group Benckiser Reckitt Annual Report and Financial Statements 2019 Statements Financial and Report Annual
    Rejuvenating RB Reckitt Benckiser Group plc Annual Report and FinancialStatements 2019 Reckitt Benckiser Group plc Annual Report and Financial Statements 20192018 INTRODUCTION CONTENTS Strategic Report Welcome 01 Financial highlights 02 Health and Hygiene Home – at a glance 04 Chairman’s statement 06 Chief Executive’s statement 10 Our business model Our purpose 12 How purpose drives our performance We exist to protect, heal and nurture in the relentless pursuit of a cleaner 14 Mapping what matters to our stakeholders and healthier world. 18 KPIs 20 Consumers Our fight 24 Customers We have a fight on our hands. A fight to make access to the highest quality 28 People hygiene, wellness and nourishment a right and not a privilege. 32 Partners 36 Communities 40 Environment 46 s172 statement 48 Health operating review 52 Hygiene Home operating review 56 Non-financial information statement 58 Financial review 64 Risk management Health 77 Viability statement Governance 78 Board of Directors 84 Executive Committee 86 Corporate Governance – Chairman’s statement 88 Corporate Governance statement 97 Nomination Committee Report 103 Audit Committee Report 111 CRSEC Committee Report 117 Directors’ Remuneration Report 138 Report of the Directors Page 48 141 Statement of Directors’ Responsibilities Financial Statements 143 Independent Auditors Report Chief Executive’s Statement 152 Financial Statements 223 Shareholder Information Hygiene Home Page 06 Page 52 STRATEGIC REPORT GOVERNANCE FINANCIAL STATEMENTS FINANCIAL HIGHLIGHTS Net Revenue Health Hygiene
    [Show full text]
  • MARKETING FARMACEUTICO (Farmaco, Parafarmaco E Otc)
    Percorso di lettura a cura di Largo Consumo Rivista di economia a marketing sulla filiera dei beni di consumo www.largoconsumo.info Documento in versione interattiva: www.largoconsumo.info/112006/PL-1106-009.Pdf MARKETING FARMACEUTICO (Farmaco, Parafarmaco e Otc) Costi del Percorso di lettura: Per ordini: [email protected] € 178,50 (comprensivo iva) - non abbonati Aggiornato a: Largo Consumo 11/2006 e supplementi € 159,00 (comprensivo iva) - abbonati Rif: PL-1106-009 Costi dei singoli titoli: http://www.largoconsumo.info/Largoconsumo/fixed/largoconsumo/pagine/diffusione.asp#Costi RIFERIMENTI: Il sommario di tutti i Percorsi di lettura di Largo Consumo è scaricabile all’indirizzo WWW.LARGOCONSUMO.INFO/PERCORSI LE FONTI DI QUESTO PERCORSO DI LETTURA E SUGGERIMENTI PER L’APPROFONDIMENTO DEI TEMI: Largo Consumo OSSERVATORIO Rivista di economia e marketing sulla filiera dei beni di consumo D’IMPRESA: Mensile fondato nel 1980 e diffuso esclusivamente in abbonamento, i cui contenuti giornalistici si sviluppano in forma di inchieste, studi e articoli vari inerenti tutti i Leggi le case history momenti della filiera dei beni mass market, food e non food., dalla produzione, alla di COMUNICAZIONI distribuzione, al consumo finale, compresi i servizi, le strutture e i sistemi collegati. D’IMPRESA di Aziende e Mercato & Imprese Organismi attivi nei Opinioni e prospettive dall’industria del largo consumo mercati considerati Ogni anno, Mercato & Imprese ospita interviste ad alcuni fra i più accreditati in questo Percorso di esponenti di aziende di primo piano dell’industria alimentare e grocery non food. I lettura selezionati contenuti giornalistici sono sviluppati in forma di interviste, tante quanti sono i da Largo Consumo settori merceologici presi in esame nel fascicolo.
    [Show full text]
  • OTC Bulletin,10 Septem- with New Names in the UK Through the Acquisition, the Swedish Com- Ber 2010, Page 1)
    OTC16-11-10p1FIN.qxd 15/11/10 07:02 Page 1 16 November 2010 COMPANY NEWS 3 Sanofi expands in China Alliance Boots eyes 3 Chinese expansion Regulatory problems hit 4 Mucinex launch with BMP Sunstone deal Reckitt plans future 5 of Durex and Scholl Merck overcomes 6 anofi-Aventis is set to strengthen its pres- der exclusive multi-year licenses and provides Latin American drop Sence in the Chinese OTC market by ac- pharmaceutical distribution services through Sanofi-Aventis works on 7 quiring BMP Sunstone and its portfolio of subsidiaries in Beijing and Shanghai. consumer acquisitions OTC cough/cold and women’s health brands Sanofi-Aventis said the US$10.00 per share Energy drinks boost 8 for around US$520 million (C375 million). deal had been unanimously approved by BMP OTC sales at Taisho The price tag represents around 3.5-times Sunstone’s board of directors and had received Prilosec OTC holds back 9 BMP Sunstone’s 2009 sales of US$147 million the backing of shareholders representing 23% growth at P&G and 62-times its operating profit of US$8.4 mil- of the company’s stock. Perrigo sees longevity 10 lion. The company is based in the US and oper- Combining BMP Sunstone with its exist- in store-brands ates through subsidiaries in China. ing Chinese joint venture business, Hangzhou Pfizer benefits from 12 Almost 60% of BMP Sunstone’s sales were Sanofi Minsheng Consumer Healthcare, would Wyeth’s OTC brands generated by its OTC brands, Sanofi-Aventis turn Sanofi-Aventis into a “leading consumer Key brands boost 13 said, which included China’s leading paediatric healthcare company in China”, the French firm Bayer Consumer Care cough and cold product Hao Wa Wa (Good- said, with a strong position in China’s two largest Merck eyes global future 15 Baby) and the women’s hygiene brand Kang OTC categories of cough and cold and vitamin for Consumer Care division Fu Te (Confort).
    [Show full text]
  • Statistical Analysis Plan
    Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version V1.4 Date 14 July 2017 Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) An observational study evaluating the benefits of early intervention with maintenance therapies to prevent or slow down rapid lung function decline in patients who are at high risk at the time of COPD diagnosis in the combined Optimum Patient Care Research Database and Clinical Practice Research Datalink databases TITLE PAGE Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version 14 July 2017 Date 14 July 2017 TABLE OF CONTENTS PAGE TITLE PAGE ........................................................................................................... 1 TABLE OF CONTENTS ......................................................................................... 2 LIST OF ABBREVIATIONS .................................................................................. 5 RESPONSIBLE PARTIES ...................................................................................... 6 PROTOCOL SYNOPSIS DIAPLO STUDY ........................................................... 7 AMENDMENT HISTORY ................................................................................... 12 MILESTONES ....................................................................................................... 13 1. BACKGROUND AND RATIONALE .................................................................. 14 1.1 Background ...........................................................................................................
    [Show full text]
  • Acquisition Agreement for SSL International -- Current Agreements
    Dealdoc Acquisition agreement for SSL International Reckitt Benckiser SSL International Jul 21 2010 © 2009-2021, Wildwood Ventures Ltd. All rights reserved. Acquisition agreement for SSL International Reckitt Benckiser Companies: SSL International Announcement date: Jul 21 2010 Deal value, US$m: 3900.0 : transaction value • Details • Financials • Termsheet • Press Release • Filing Data • Contract Details Announcement date: Jul 21 2010 Industry sectors: Consumer health Financials Deal value, US$m: 3900.0 : transaction value Termsheet 21 July 2010 Reckitt Benckiser has agreed to buy Durex condom maker SSL International for 2.54 billion pounds. Press Release RECOMMENDED CASH OFFER FOR SSL INTERNATIONAL PLC BY RECKITT BENCKISER PLC, A WHOLLY-OWNED SUBSIDIARY OF RECKITT BENCKISER GROUP PLC Summary of the Offer The boards of Reckitt Benckiser Group plc ("Reckitt Benckiser") and SSL International plc ("SSL") are pleased to announce that they have reached agreement on the terms of a recommended cash offer to be made by Reckitt Benckiser plc, a wholly-owned subsidiary of Reckitt Benckiser, to acquire the entire issued and to be issued share capital of SSL (the “Offer”). SSL is a focused consumer products company with leading global brands such as Durex and Scholl, as well as a portfolio of local brands. Reckitt Benckiser is a world leader in household and health & personal care. The acquisition of SSL provides Reckitt Benckiser with an attractive opportunity to increase its presence in the health & personal care sector. Under the terms of the Offer, SSL Shareholders will be entitled to receive 1163 pence in cash per SSL Share (the “Offer Price”) and will also remain entitled to receive the proposed final dividend of 8 pence per share in respect of the year ended 31 March 2010 (the “SSL Dividend”), representing, in aggregate, 1171 pence per SSL Share.
    [Show full text]
  • Annual Report and Financial Statements 2016 Reckitt Benckiser Group Plc (RB) Annual Report and Financial Statements 2016
    Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements 2016 Reckitt Benckiser Group plc (RB) plc Group Benckiser Reckitt Annual Report and Financial Statements 2016 Purpose with a passion Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements 2016 RB has a vision of a world where people are healthier and live better lives. Inspired by our purpose and a passionate culture that drives ownership and rewards success, we push ourselves to outperform, every day. Our purpose Our passion Our performance See more on pages See more on pages 4-5 See more on pages 6-7 2-3 2 3 4 5 6 7 Strategic Report Strategic Report Strategic Report Strategic Report Strategic Report Strategic Report Governance Governance Governance Governance Governance Governance Financial Statements Financial Statements Financial Statements Financial Statements Financial Statements Financial Statements Why RB delivers Our purpose… …combined with …drives our (out) Right portfolio strategy We identify unmet consumer needs, drive growth through innovation and invest our passion performance disproportionately behind our high-potential markets (Powermarkets) and our faster- growing brands (Powerbrands). Our purpose inspires us and informs what we do. RB has a unique culture that harnesses Bringing together passionate people and With every decision, we look for innovative solutions that Our purpose is to make the passion of our people. We have a compelling We want our people to behave as giving them a clear purpose makes RB a business where Powerbrands Powermarkets can help our consumers to live better, from new products a difference, by giving people desire to challenge ourselves and each other, if they own the business.
    [Show full text]
  • SSL International Puts Best Foot Forward with Hybris and Javelin Group’S Camelcommerce Submitted By: Ascendant Communications Friday, 17 July 2009
    SSL International puts best foot forward with hybris and Javelin Group’s CamelCommerce Submitted by: Ascendant Communications Friday, 17 July 2009 ...Online sales for Scholl brand doubled in the UK following implementation of hybris and CamelCommerce e-commerce platform to support direct sales strategy... London – 17 July 2009. hybris (www.hybris.com), a multi-channel commerce and communication software vendor, and Javelin Group (www.javelingroup.com), an e-commerce consultancy and systems integrator, have together announced the successful implementation of a new best practice B2C e-commerce website for Scholl in the UK, based on hybris and Javelin Group’s CamelCommerce e-commerce platform. Scholl, the global footwear and footcare brand, is part of the SSL International portfolio of brands, which also includes Durex and a range of locally-owned over the counter (OTC) products such as Full Marks, Medised and Paramol in the UK. Scholl brands range from its Party Feet gel insole range to Flight Socks and the iconic Scholl Pescura sandal, which is 50 years old this year. The launch of the revised UK e-commerce website for Scholl has led to a significant increase in online sales and web traffic for www.scholl.com. It also marks the first phase in SSL International’s long-term commitment to providing direct consumer interaction with the brand. SSL International, which is represented in over 100 countries throughout the world, now plans to roll-out the website to overseas markets, starting in Europe from July, followed by the consideration of emerging market requirements. Development of a B2C website for Durex, which will initially be launched in the UK later in 2009 and then rolled out around the world, is already under way.
    [Show full text]
  • Annual Report 2004
    Address Telephone Registration Number SSL International Annual Report 2004 SSL International plc +44 (0)20 7367 5760 388828 35 New Bridge Street Facsimile London +44 (0)20 7367 5790 EC4V 6BW Web www.ssl-international.com Annual Report 2004 International plc 1This is SSL International 2 Chairman’s Message £602.4m Designed and produced by 4Chief Executive’s Review williams and phoa 6 Operating Review Turnover (2003:£608.9m) 14 Corporate Social Responsibility Stated in accordance with FRS 5 Printed in the UK on paper 16 Financial Review made from 50 per cent pulp, 20 Group Board 50 per cent recycled fibres 22 Corporate Governance which is biodegradable. 24 Directors’ Report 25 Remuneration Report 31 Directors’ Responsibilities 31 Independent Auditors’ Report £74.5m to the Members of SSL International plc 32 Consolidated Profit and Loss Account Operating profit (2003:£82.0m) 33 Consolidated and Company Before charging exceptional items Balance Sheets 34 Consolidated Cash Flow Statement 35 Consolidated Statement of Total Recognised Gains and Losses 35 Reconciliation of Movements in Shareholders’ Funds 36 Notes to the Financial Statements £(7.5)m 65 Five Year Record 66 SSL Directory (Loss)/profit before tax 68 Company Information (2003:£39.1m) 68 Financial Calendar After charging exceptional items (4.2)p Basic (loss)/earnings per share (2003:13.1p) After charging exceptional items 8.1p Dividend per share (2003:12.3p) £227.5m Net debt (2003:£292.0m) £85.2m Free cash flow (2003:£39.1m) This is SSL International A focused global consumer healthcare company Consumer division Medical and industrial glove Manufacturing The Consumer division represented divestment programme Our manufacturing facilities are £408.2 million or 68 per cent As part of our stated strategy primarily located in the Far East of Group sales.
    [Show full text]
  • Novartis Set to Introduce Pantoloc in 14 Countries
    OTC10-02-10p1FIN.qxd 8/2/10 07:43 Page 1 10 February 2010 COMPANY NEWS 2 Novartis set to introduce Switzerland’s Mepha aims 2 at herbals and supplements Alliance Boots to establish 3 Swedish pharmacy venture Pantoloc in 14 countries Ta isho suffers as OTC market cools 4 J&J hit by comparison and currency 6 ovartis Consumer Health is set to in- the product is available without a prescription Ntroduce Nycomed’s proton-pump in- in Australia. NBTY’s pre-tax profits soar 7 hibitor Pantoloc Control as a non-prescrip- Novartis said that it would introduce Panto- Demand for OTC specialties 8 tion medicine in 14 European countries. loc Control in the 14 countries “later in 2010” lifts annual sales at Boiron The 20mg pantoprazole tablets gained non- through a co-marketing agreement with Nyco- Prilosec OTC hit by Prevacid 9 prescription status across Europe in June of last med. “The launch will be backed by substan- MiraLAX rival drives Perrigo 10 year through the European Union’s centralis- tial investment to build consumer awareness Omega offsets tough 11 ed authorisation procedure (OTC bulletin,19 and demand,”the company commented, “as start to grow sales June 2009, page 1). well as pharmacy training to help pharmacy Cadbury’s shareholders agree 12 Nycomed has since introduced the medi- teams identify customers who will benefit most to Kraft takeover cine for frequent heartburn in Austria, Estonia, from Pantoloc Control and advise those cus- William Ransom agrees to 13 Finland, France, Germany, Hungary,Latvia, tomers appropriately.” divest Manuka Gold Lithuania, the Netherlands,Norway,Poland, Brian McNamara, head of Europe for Nov- GENERAL NEWS 14 Sweden and Switzerland.
    [Show full text]
  • Business Acquisition Section 66: Notice Seeking Clearance
    Public Version COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE Date: 28 February 2019 The Registrar Competition Branch Commerce Commission PO Box 2351 Wellington Pursuant to section 66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. DOC REF 24002354 Clearance Application Public Version Part A: Summary of Application 1. Executive Summary This clearance application concerns the proposed acquisition by GlaxoSmithKline plc. (GSK) of Pfizer’s consumer healthcare business (Pfizer CH), resulting in the combination of the consumer health (CH) businesses of GSK (GSK CH) and Pfizer (Pfizer CH) into a new company under the majority ownership and control of GSK (the Combined CH Business), (the Proposed Transaction). GSK will have a majority controlling equity interest of 68% in the Combined CH Business and Pfizer will have a minority non-controlling equity interest of 32%. The Proposed Transaction involves a range of consumer health products. However, material competitive overlaps arise only in relation to over the counter (OTC) cold and flu treatments and OTC pain management products. Based on certain pharmaceutical categorisations, there are a small number of additional products for which an overlap could be said to exist, but where the products do not in any way compete. The lack of competitive overlap is described further in the market definition section. Cold and flu treatments (a) In the cold and flu treatments market the Proposed Transaction will combine in the Combined CH Business GSK’s Panadol Cold & Flu MAX, Coldrex1 and Otrivin products with Pfizer’s Dimetapp and Robitussin products.
    [Show full text]
  • 2010 Annual Report
    Driving innovative growth Annual Report and Financial Statements 2010 I am pleased to report that Reckitt Benckiser enjoyed another year of market beating results despite a £8,453m our net revenue global market growth rate that steadily declined as the year progressed. As targeted for 2010, we delivered like-for-like net revenue £2,231m adjusted operating profit growth of +6%* for the Group excluding SSL, and +5%* for the business excluding SSL and RB Pharmaceuticals. ** Total adjusted income growth at +15%* was also very strong 115.0p and again well ahead of our peers. dividend per share Bart Becht Chief Executive * at constant exchange rates ** Includes final 2010 dividend of 65p recommended by the Board Contents 1 Chairman’s Statement 2 Chief Executive’s Statement 4 Business review 2010 12 Board of Directors and Executive Committee 13 Report of the Directors 17 Corporate governance report 21 Statement of Directors’ responsibilities 22 Directors’ remuneration report 29 Independent auditors’ report to the members of Reckitt Benckiser Group plc 30 Group income statement 30 Group statement of comprehensive income 31 Group balance sheet 32 Group statement of changes in equity 33 Group cash flow statement 34 Notes to the accounts 64 Five year summary 65 Parent company – independent auditors’ report to the members of Reckitt Benckiser Group plc 66 Parent company balance sheet 67 Notes to the parent company accounts 72 Shareholder information Chairman’s Statement Strong performance at Tesco plc. She was seven years at Tesco, In 2010 your Company delivered a strong having joined from Unilever PLC, where she performance.
    [Show full text]